Development and characterization of stabilized double loaded mPEG-PDLLA micelles for simultaneous delivery of paclitaxel and docetaxel

References

• Tije AJt, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokin 2003;42:665–85
   PubMed Web of Science ®Google Scholar
• Weiss R, Donehower R, Wiernik P, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263–8
   PubMed Web of Science ®Google Scholar
• Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL® and its derivatives: oxethylated oleic acid is the most effective constituent. J Inflamm Res 1977;7:63–7
   Google Scholar
• Dye D, Watkins J. Suspected anaphylactic reaction to Cremophor EL. Brit Med J 1980;280:1353
   PubMed Web of Science ®Google Scholar
• Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharma 1996;132:195–206
   Web of Science ®Google Scholar
• Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. Journal of Controlled Release 2001;72:191–202
   PubMed Web of Science ®Google Scholar
• Kim DW, Kim SY, Kim HK, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:2009–14
   PubMed Web of Science ®Google Scholar
• Lee KS, Chung HC, Im SA, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008;108:241–50
   PubMed Web of Science ®Google Scholar
• Le GD, Gori S, Luo L, et al. Poly(N-vinylpyrrolidone)-block-poly(d,l-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Control Release 2004;99:83–101
   PubMed Web of Science ®Google Scholar
• Liang HJ, Yang QX, Deng L, et al. Phospholipid–Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel. Drug Dev Ind Pharm 2011;37:597–605
   PubMed Web of Science ®Google Scholar
• Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708–16
   PubMed Web of Science ®Google Scholar
• Lim WT, Tan EH, Toh CK, et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 2010;21:382–8
   PubMed Web of Science ®Google Scholar
• Lee SW, Chang DH, Shim MS, et al. Ionically fixed polymeric nanoparticles as a novel drug carrier. Pharm Res 2007;24:1508–16
   PubMed Web of Science ®Google Scholar
• Finley RS, Balmer C. Optimizing chemotherapy outcome. In: Finley RS, Balmer C, eds. Concepts in oncology therapeutics. Bethesda (MD): American Society of Health-System Pharmacists; 1998:87–9
   Google Scholar
• Zhou Y, Feng L, Mueller T, et al. 17-AAG (KOS-953), an inhibitor of Hsp90 function, significantly enhances the cytotoxicity of anticancer drugs: an effective approach for combination therapy. AACR Meeting Abstracts 2004;2004:458-b
   Google Scholar
• Xiao L, Rasouli P, Ruden DM. Possible effects of early treatments of Hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs. Curr Medicinal Chem 2007;14:223–32
   PubMed Web of Science ®Google Scholar
• Min-Hyo S, Yil-woong Y, Jae-Won Y. Stable polymeric micelle-type drug composition and method for the preparation thereof. US Patent Application Publication 2003; Patent No. US2003/0143184 A1
   Google Scholar
• Shin HC, Alani AW, Rao DA, et al. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release 2009;140:294–300
   PubMed Web of Science ®Google Scholar
• Sciencelab.com Inc. Pyrene; 2009. Available from: http://www.sciencelab.com/xMSDS-Pyrene-9924760 [last accessed 15 Dec 2012]
   Google Scholar
• Knox C, Wishart D. Paclitaxel; 2009. Available from: http://www.drugbank.ca/drugs/DB01229 [last accessed 15 Dec 2012]
   Google Scholar
• Knox C, Wishart D. Docetaxel; 2009. Available from: http://www.drugbank.ca/drugs/DB01248 [last accessed 15 Dec 2012]
   Google Scholar
• Ouahab A, Shen Y, Tu JS. Novel oral delivery system of indomethacin by solidified mPEG-PDLLA micelles: in vivo study. Drug Deliv 2012;19:232–7
   PubMed Web of Science ®Google Scholar
• Cho YW, Lee J, Lee SC, et al. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release 2004;97:249–57
   PubMed Web of Science ®Google Scholar
• Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17:1263–8
   PubMed Web of Science ®Google Scholar
• Riley T, Stolnik S, Heald CR, et al. Physicochemical evaluation of nanoparticles assembled from poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) block copolymers as drug delivery vehicles. Langmuir 2001;17:3168–74
   Web of Science ®Google Scholar
• Turro NJ, Kuo PL. Fluorescence probes for aqueous solutions of nonionic micelles. Langmuir 1985;1:170–2
   Web of Science ®Google Scholar
• Royal Society of Chemistry. Tanespimycin; 2007. Available from: http://www.chemspider.com/21106220 [last accessed 7 March 2013]
   Google Scholar
• Hansch C, Hoekman D, Leo A, et al. Etoposide; 1995. Available from: http://www.drugbank.ca/drugs/DB00773 [last accessed 7 March 2013]
   Google Scholar
• Hasenstein JR, Shin HC, Kasmerchak K, et al. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther 2012;11:2233–42
   PubMed Web of Science ®Google Scholar
• Straubinger RM, Balasubramanian SV. Preparation and characterization of taxane-containing liposomes. Methods Enzymol 2005;391:97–117
   PubMed Web of Science ®Google Scholar
• Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191–202
   PubMed Web of Science ®Google Scholar
• Dorr RT. Pharmacology of the taxanes. Pharmacotherapy 1997;17:96S–104S
   PubMed Web of Science ®Google Scholar
• Chimming R, Mason KA, Hunter N, et al. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 1999;43:165–72
   Web of Science ®Google Scholar
• Berta O, Radka VCk, Vlasta D, et al. Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague–Dawley/Cub rats. Eur J Pharm Sci 2006;29:442–50
   PubMed Web of Science ®Google Scholar
• hrlichová M, Václavíkova R, Ojima I, et al. Transport and cytotoxicity of paclitaxel, docetaxel and three novel taxanes in human breast cancer cells N-S Arch. Pharmacol 2005;372:95–105
   Web of Science ®Google Scholar
• Izquierdo MA, Garcia M, Ponton JL, et al. A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours. Eur J Cancer 2006;42:1789–96
   PubMed Web of Science ®Google Scholar
• Lokich J. Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors. Cancer 2000;89:2309–14
   PubMed Web of Science ®Google Scholar
• Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19:125–41
   PubMed Web of Science ®Google Scholar
• Majeti NV, Ravi K, Neeraj K. Polymeric controlled drug-delivery systems: perspective issues and opportunities. Drug Dev Ind Pharm 2001;27:1–30
   PubMed Web of Science ®Google Scholar
• Ki YC, Kyung HM, Hong YY, et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 2011;32:1880–9
   PubMed Web of Science ®Google Scholar